Dr. christopher ames to join aclarion as a key opinion leader surgeon advisor

Broomfield, co, dec. 22, 2022 (globe newswire) -- via  newmediawire  -- aclarion, inc., (“aclarion” or the “company”) (nasdaq: acon, aconw), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that dr. christopher ames, director of spinal deformity and spine tumor surgery and co-director of the combined high risk spine service, the neurospinal disorders program, and the ucsf spine center at the university of california at san francisco will advise the company as a key opinion leader (kol) nationally.
ACON Ratings Summary
ACON Quant Ranking